Animal model experiments show that a mixture of LA85 and BLa80 can alleviate the inflammation caused by H. pylori infection. The combination of these strains proves more effective in relieving inflammation than either strain alone.

The fermentation system of WECARE Probiotics Intelligent Manufacturing Factory has set an industry benchmark with the advantages of scale, intelligence, and refinement. The system integrates an intelligent and fully automated fermentation process, achieving full pipeline transportation of materials. It is equipped with a 30 ton ultra large capacity single fermentation tank, with a total fermentation capacity of up to 400 tons.

This probiotic patent focuses on a dual-strain formulation targeting osteoporosis improvement. The formulation contains Limosilactobacillus reuteri LR38 and Lacticaseibacillus rhamnosus LRa05, which together exhibit synergistic effects on bone health by mitigating bone density loss and decreasing osteoclastogenic factors.

Las Vegas, NV – The curtains officially opened on the much-anticipated SupplySide West 2024 exhibition in Las Vegas, marking a pivotal moment for the global natural, health, and innovative ingredients industry. At the heart of this prestigious event, WECARE shone brightly as the official category sponsor, commanding a prime presence at booth number 6643.

This patent discusses a probiotic agent aimed at improving hypertension, composed primarily of the Akkermansia muciniphila Akk11 and Lacticaseibacillus rhamnosus LRa05.

This probiotic composition, containing Akkermansia muciniphila Akk11 and Lactobacillus johnsonii LJ09, offers a novel and safe approach to managing hyperuricemia. Its synergistic action not only regulates uric acid levels but also protects the kidneys, reducing the risk of complications associated with high uric acid.